UOC
AKTX

UBS O'Connor’s Akari Therapeutics AKTX Stock Holding History

UBS O'Connor’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-372
Closed -$1.29M – 299
2017
Q4 		$1.29M Buy
+372
New +$1.43M 0.02% 224

Other funds holding AKTX

HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS O'Connor's AKTX Position: Q1 2018 in Review

UBS O'Connor sold out of Akari Therapeutics (AKTX) in Q1 2018, closing a stake of 372 shares — an estimated $1.29M sold.

UBS O'Connor first reported a position in AKTX in Q4 2017 and held it in 1 quarter. The position peaked at $1.29M in Q4 2017. 9 funds tracked by Wall St. Rank hold AKTX as of Q1 2018.

  • UBS O'Connor reported no remaining Akari Therapeutics position as of Q1 2018 after selling out during the quarter.
  • UBS O'Connor sold 372 Akari Therapeutics shares in Q1 2018, an estimated $1.29M.
  • UBS O'Connor first reported a position in Akari Therapeutics in Q4 2017 and held it in 1 quarter.
  • UBS O'Connor's Akari Therapeutics position peaked at $1.29M in Q4 2017.
  • 9 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2018.

Based on UBS O'Connor's 13F filing for Q1 2018, filed 14 May 2018.